Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Purchased by Royce & Associates LP

Royce & Associates LP boosted its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1.7% in the third quarter, HoldingsChannel reports. The firm owned 305,855 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,966 shares during the quarter. Royce & Associates LP’s holdings in Collegium Pharmaceutical were worth $11,818,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Caxton Associates LP bought a new position in shares of Collegium Pharmaceutical in the first quarter valued at approximately $1,730,000. Foundry Partners LLC bought a new stake in Collegium Pharmaceutical during the second quarter worth approximately $492,000. O Shaughnessy Asset Management LLC lifted its position in shares of Collegium Pharmaceutical by 159.3% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 45,735 shares of the specialty pharmaceutical company’s stock valued at $1,775,000 after acquiring an additional 28,100 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Collegium Pharmaceutical by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after acquiring an additional 17,942 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its position in shares of Collegium Pharmaceutical by 194.5% in the 2nd quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock valued at $3,553,000 after acquiring an additional 72,874 shares in the last quarter.

Insider Activity

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The trade was a 15.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the sale, the executive vice president now owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. This represents a 13.81 % decrease in their position. The disclosure for this sale can be found here. 3.98% of the stock is owned by company insiders.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $29.58 on Friday. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm has a market capitalization of $953.96 million, a price-to-earnings ratio of 12.75 and a beta of 0.95. The company’s fifty day moving average is $36.36 and its two-hundred day moving average is $35.01. Collegium Pharmaceutical, Inc. has a 52-week low of $24.61 and a 52-week high of $42.29.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on COLL shares. Piper Sandler reiterated a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Truist Financial raised their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, HC Wainwright raised their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, September 5th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $42.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.